•  
  •  
 

Bulletin of Chinese Academy of Sciences (Chinese Version)

Keywords

biomedical technology, international cooperation, patent analysis, social network analysis, China-U.S. cooperation

Document Type

Information & Observation

Abstract

In light of the rapid advancement of biomedical technologies and intensifying geopolitical competition over technological dominance, international cooperation in this field has garnered significant attention among scholars, policymakers, and industry leaders. This study employs comprehensive patent data spanning from 2002 to 2023 across the global biomedical landscape to systematically investigate the characteristics and evolution patterns of both global and Chinese biomedical inventions. Employing econometric analysis of patents and social network analysis, the research examines three key dimensions: patent output, technological pathways, and collaboration networks. Three research findings are derived. Firstly, China has transitioned from a “catch-up collaborator” to a critical hub facilitating cross-national and cross-disciplinary knowledge flows. Despite challenges posed by U.S. technological decoupling policies, China remains deeply embedded in the global technology system. Amid escalating geopolitical tensions, China-Western cooperation is undergoing strategic rebalancing, as China expands its collaboration with emerging economies and Belt and Road countries to build a more diverse, resilient, and adaptive global biomedical cooperation network. Secondly, China is progressively strengthening its technological leadership within international collaborations. Antibody-based technologies have emerged as a central area of cooperation, reflecting a shift from traditional broad-spectrum formulations to precision-targeted therapies and high-complexity drug delivery systems. This transformation underscores China’s evolving role-from a recipient of general-purpose technologies to a co-creator of frontier innovations-increasingly integrated into the global high-end biomedical innovation ecosystem. However, significant gaps persist compared to developed economies, particularly in upstream capabilities such as platform technologies, fundamental pharmaceutical chemistry, and gene editing. Thirdly, while the U.S. and European countries continue to lead global technological paradigms in foundational and platform technologies-shaping a pattern of strategic complementarity-China-U.S. cooperation remains concentrated in midstream R&D activities within the industrial chain. This collaboration is characterized by a consensus-driven, market-oriented approach, focusing on functional modifications and applied innovations based on existing targets rather than constructing differentiated knowledge assets from the ground up. Consequently, a stable framework for long-term complementarity and platform-level coordination has yet to be established. This study contributes to a deeper understanding of the evolutionary mechanisms underlying China’s transformation from a “technology taker” to a “network orchestrator” within the global biomedical collaboration landscape. From a policy perspective, it offers valuable insights for advancing China's strategy of high-level scientific and technological openness and building a strategically influential and internationally embedded innovation system. Specifically, the study proposes five policy implications for China. (1) Establish strategic international joint R&D platforms to enhance China’s embeddedness in critical innovation nodes. (2) Guide resource allocation toward high-barrier, highly original technological domains to strengthen China’s control within the global value chain. (3) Optimize incentive mechanisms for cross-border collaboration to attract high-quality international cooperation resources to China. (4) Fortify the national bio-data defense system and develop an autonomous and controllable biomedical data ecosystem. (5) Encourage the participation of diverse actors in international collaboration networks to enhance China’s influence in high-quality collaborative patents.

First page

2061

Last Page

2075

Language

Chinese

Publisher

Bulletin of Chinese Academy of Sciences

References

1. 马晓玲. 美国建设生物医药创新高地的实践及对我国的启示. 中国科学院院刊, 2023, 38(2): 294-301. Ma X L. Practice of building biomedical innovation highland in the United States and its enlightenment to China. Bulletin of Chinese Academy of Sciences, 2023, 38(2): 294-301. (in Chinese)

2. 刘海涛. 我国生物医药产业高质量发展的现状、挑战与应对. 经济界, 2025, (1): 82-87. Liu H T. Strategies and solutions to the challenges faced by China’s biomedicine industry in the context of high-quality development. Economic Affairs, 2025, (1): 82-87. (in Chinese)

3. 余振, 秦宁. 美国生物经济发展战略的新动向、影响及我国对策. 国际贸易, 2023, (7): 12-21. Yu Z, Qin N. New Trends, influences, and countermeasures of American bioeconomy development strategy. Intertrade, 2023, (7): 12-21. (in Chinese)

4. Wang F. Does the recombination of distant scientific knowledge generate valuable inventions? An analysis of pharmaceutical patents. Technovation, 2024, 130: 102947.

5. 钟华, 胥美美, 苟欢, 等. 全球基因编辑技术专利布局与发展态势分析. 世界科技研究与发展, 2022, 44(2): 241-243. Zhong H, Xu M M, Gou H, et al. Analysis on patent layout and development trend of global gene editing technology. World Sci-Tech R & D, 2022, 44(2): 241-243. (in Chinese)

6. 张巍巍, 管同. 基因治疗伦理研究的主题聚类与演进. 医学与哲学, 2025, 46(4): 39-44. Zhang W W, Guan T. Thematic clustering and evolution of gene therapy ethical research. Medicine and Philosophy, 2025, 46(4): 39-44. (in Chinese)

7. 叶玉江. 持之以恒加强基础研究夯实科技自立自强根基. 中国科学院院刊, 2022, 37(5): 589-595. Ye Y J. Continuously strengthening basic research and solidifying foundation of sci-tech self-reliance and self-strengthening. Bulletin of Chinese Academy of Sciences, 2022, 37(5): 589-595. (in Chinese)

8. Graul A I, Sorbera L A. The year’s new drugs and biologics 2020. Drugs of Today, 2021, 57(2): 101-177.

9. 孙雪林, 谭雪莹, 金鹏飞, 等. 新型抗肿瘤药物致心脏毒性的文献计量学分析. 临床药物治疗杂志, 2024, 22(11): 73-78. Sun X L, Tan X Y, Jin P F, et al. Bibliometric analysis of cardiotoxicity due to novel antitumor drugs. Clinical Medication Journal, 2024, 22(11): 73-78. (in Chinese)

10. Groff-Vindman C S, Trump B D, Cummings C L, et al. The convergence of AI and synthetic biology: The looming deluge. NPJ Biomedical Innovations, 2025, 2: 20.

11. 刘晓, 曾艳, 王力为, 等. 创新政策体系保障合成生物学科技与产业发展. 中国科学院院刊, 2018, 33(11): 1260-1268. Liu X, Zeng Y, Wang L W, et al. Innovative policy system to ensure the development of synthetic biology. Bulletin of Chinese Academy of Sciences, 2018, 33(11): 1260-1268. (in Chinese)

12. 郑永年, 徐兰朦. 以大科创体系“多轨并举”推动中国现代产业体系建设. 中国科学院院刊, 2025, 40(5): 795-808. Zheng Y N, Xu L M. Promoting construction of China’s modern industrial system by “multi-tracking” research and innovation model. Bulletin of Chinese Academy of Sciences, 2025, 40(5): 795-808. (in Chinese)

Download
Request a Copy

Share

COinS